Leigh Anderson Launches New Firm to Commercialize SISCAPA Technology | GenomeWeb

By Adam Bonislawski

This article was originally posted on June 14.

Proteomics researcher Leigh Anderson has formed a new company to commercialize SISCAPA, the immunoaffinity-based mass spec assay he developed.

Launched last week at the American Society for Mass Spectrometry's annual meeting, the firm – SISCAPA Assay Technologies – is currently focused on selling assay development services to customers interested in using SISCAPA technology, Anderson told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.